These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 34844537)

  • 1. A
    Merighi S; Borea PA; Varani K; Vincenzi F; Jacobson KA; Gessi S
    Curr Med Chem; 2022; 29(24):4138-4151. PubMed ID: 34844537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiological Role and Medicinal Chemistry of A
    Merighi S; Borea PA; Varani K; Vincenzi F; Travagli A; Nigro M; Pasquini S; Suresh RR; Kim SW; Volkow ND; Jacobson KA; Gessi S
    Molecules; 2022 Apr; 27(9):. PubMed ID: 35566035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and Structural Insight into Adenosine A
    Karati D; Mukherjee S; Roy S
    Mol Neurobiol; 2023 Oct; 60(10):5987-6000. PubMed ID: 37391647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A
    Lambertucci C; Marucci G; Catarzi D; Colotta V; Francucci B; Spinaci A; Varano F; Volpini R
    Curr Med Chem; 2022 Aug; 29(28):4780-4795. PubMed ID: 35184706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caffeine for Prevention of Alzheimer's Disease: Is the A
    Merighi S; Travagli A; Nigro M; Pasquini S; Cappello M; Contri C; Varani K; Vincenzi F; Borea PA; Gessi S
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.
    Rivera-Oliver M; Díaz-Ríos M
    Life Sci; 2014 Apr; 101(1-2):1-9. PubMed ID: 24530739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of adenosine A
    Silva AC; Lemos C; Gonçalves FQ; Pliássova AV; Machado NJ; Silva HB; Canas PM; Cunha RA; Lopes JP; Agostinho P
    Neurobiol Dis; 2018 Sep; 117():72-81. PubMed ID: 29859867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A
    Merighi S; Nigro M; Travagli A; Pasquini S; Borea PA; Varani K; Vincenzi F; Gessi S
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulating Alzheimer's disease through caffeine: a putative link to epigenetics.
    Marques S; Batalha VL; Lopes LV; Outeiro TF
    J Alzheimers Dis; 2011; 24 Suppl 2():161-71. PubMed ID: 21427489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of adenosine A2A receptors in depression and anxiety.
    Yamada K; Kobayashi M; Kanda T
    Int Rev Neurobiol; 2014; 119():373-93. PubMed ID: 25175973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A2A adenosine receptor deletion is protective in a mouse model of Tauopathy.
    Laurent C; Burnouf S; Ferry B; Batalha VL; Coelho JE; Baqi Y; Malik E; Mariciniak E; Parrot S; Van der Jeugd A; Faivre E; Flaten V; Ledent C; D'Hooge R; Sergeant N; Hamdane M; Humez S; Müller CE; Lopes LV; Buée L; Blum D
    Mol Psychiatry; 2016 Jan; 21(1):97-107. PubMed ID: 25450226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A2A adenosine receptor antagonism enhances synaptic and motor effects of cocaine via CB1 cannabinoid receptor activation.
    Tozzi A; de Iure A; Marsili V; Romano R; Tantucci M; Di Filippo M; Costa C; Napolitano F; Mercuri NB; Borsini F; Giampà C; Fusco FR; Picconi B; Usiello A; Calabresi P
    PLoS One; 2012; 7(6):e38312. PubMed ID: 22715379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of cannabinoid signaling in microglia by adenosine A
    Franco R; Reyes-Resina I; Aguinaga D; Lillo A; Jiménez J; Raïch I; Borroto-Escuela DO; Ferreiro-Vera C; Canela EI; Sánchez de Medina V; Del Ser-Badia A; Fuxe K; Saura CA; Navarro G
    Glia; 2019 Dec; 67(12):2410-2423. PubMed ID: 31429130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Caffeine, Chocolate and Adenosine A2A Receptor Antagonists in the Treatment of Parkinson's Disease].
    Reichmann H
    Fortschr Neurol Psychiatr; 2023 Jun; 91(6):256-261. PubMed ID: 35584767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
    Koch P; Akkari R; Brunschweiger A; Borrmann T; Schlenk M; Küppers P; Köse M; Radjainia H; Hockemeyer J; Drabczyńska A; Kieć-Kononowicz K; Müller CE
    Bioorg Med Chem; 2013 Dec; 21(23):7435-52. PubMed ID: 24139167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can adenosine A
    Jenner P; Mori A; Kanda T
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S28-S36. PubMed ID: 33349577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Opportunities for Caffeine and A2A Receptor Antagonists in Retinal Diseases.
    Boia R; Ambrósio AF; Santiago AR
    Ophthalmic Res; 2016; 55(4):212-8. PubMed ID: 26959995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do caffeine and more selective adenosine A
    Chen JF; Schwarzschild MA
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1(Suppl 1):S45-S53. PubMed ID: 33349580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of adenosine in Alzheimer's disease.
    Rahman A
    Curr Neuropharmacol; 2009 Sep; 7(3):207-16. PubMed ID: 20190962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential therapeutic relevance of adenosine A2B and A2A receptors in the central nervous system.
    Popoli P; Pepponi R
    CNS Neurol Disord Drug Targets; 2012 Sep; 11(6):664-74. PubMed ID: 22963436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.